ELVN · Enliven Therapeutics, Inc.
$58.92
-0.47 (-0.79%)
At close · Aug 20
Market Cap
$4.30B
Shares
73.27M
Positioning
Aug 21, 2026 · expires todayPut / call OI
—
dated and unknown snapshot sessions
Open interest
—
dated and unknown snapshot sessions
Volume
—
dated and unknown snapshot sessions
Chain
Click any strike for greeks, breakeven and the calculator| Calls | Puts | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OI | Vol | IV | Δ | Last | Strike | Last | Δ | IV | Vol | OI |
| 1 | 2 | — | — | $24.20 | — | — | — | — | 0 | |
| 0 | — | — | — | — | $0.05 | -0.074 | 1992.1% | 3 | 0 | |
| 0 | — | — | — | — | — | -0.093 | 1640.3% | — | 0 | |
| 1 | 1 | — | — | $19.04 | — | -0.115 | 1344.4% | — | 0 | |
| 0 | — | — | — | — | $0.05 | -0.056 | 638.4% | 5 | 5 | |
| 1 | 3 | — | — | $13.35 | $2.82 | -0.083 | 499.6% | 4 | 0 | |
| 67 | 20 | — | — | $7.85 | $1.25 | -0.102 | 326.5% | 70 | 114 | |
| 61 | 3 | — | — | $4.62 | $2.20 | -0.178 | 187.3% | 12 | 90 | |
| 1.2k | 33 | 105.3% | 0.359 | $0.62 | $1.55 | -0.619 | 122.7% | 1 | 1 | |
| 64 | 20 | 433.1% | 0.332 | $0.40 | — | -0.842 | 220.1% | — | 0 | |
| 5 | 1 | 354.3% | 0.141 | $0.30 | — | -0.891 | 311.2% | — | 0 | |
| 0 | — | 417.4% | 0.101 | — | — | -0.926 | 375.7% | — | 0 | |
| 0 | — | 696.6% | 0.186 | — | — | -0.936 | 446.2% | — | 0 | |
| 0 | — | 839.6% | 0.196 | — | — | -0.95 | 496.2% | — | 0 | |
| 0 | — | — | — | — | — | -0.948 | 575.2% | — | 0 | |
About this data
Each contract's last price, volume, greeks, implied volatility and open interest belongs to the snapshot session shown in its details; unknown means the provider omitted the timestamp. This chain has mixed snapshot sessions · Jun 22, 2026–Aug 20, 2026; 16 unknown. Cross-contract positioning totals are shown only when every returned row has the same known session. Bid and ask are not included on this plan.
In-the-money strikes are tinted, deepening toward the money, and the bar beside each open-interest figure scales to the heaviest strike shown.
Key facts
CIK
1672619
CUSIP
29337E102
13F (30d)
203 filings
202 filers
Visit website
Investor relations